Brief: Antengene Says U.S. FDA Ind Clearance For Phase I Trial Of Atg-017

Antengene

31/10/2022 12:35

Oct 31 (Reuters) - Antengene Corporation Ltd  6996.HK :
    * U.S. FDA IND CLEARANCE FOR PHASE I TRIAL OF- SMALL
MOLECULE
ERK1/2 INHIBITOR ATG-017 IN- PATIENTS WITH ADVANCED SOLID TUMORS
    * INVESTIGATIONAL NEW DRUG APPLICATION FOR ATG-017 HAS
RECEIVED
CLEARANCE FROM U.S. FDA

Further company coverage:  6996.HK 
 ((Reuters.Briefs@thomsonreuters.com;))